Methotrexate or azathioprine-do differing rates of discontinuation settle the debate?

Affiliations

Editorial

Alan G Fraser. Aliment Pharmacol Ther. 2020 Nov.

. 2020 Nov;52(9):1527-1528.

doi: 10.1111/apt.16076.

No abstract available

Comment in

Editorial: methotrexate vs azathioprine-do differential rates of discontinuation settle the debate? Authors' reply.
Vasudevan A, Con D, Nicolaides S, van Langenberg DR. Vasudevan A, et al. Aliment Pharmacol Ther. 2020 Nov;52(9):1529-1530. doi: 10.1111/apt.16095. Aliment Pharmacol Ther. 2020. PMID: 33263380 No abstract available.

Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease.
Vasudevan A, Parthasarathy N, Con D, Nicolaides S, Apostolov R, Chauhan A, Bishara M, Luber RP, Joshi N, Wan A, Rickard JA, Long T, Connoley D, Sparrow MP, Gibson PR, van Langenberg DR. Vasudevan A, et al. Aliment Pharmacol Ther. 2020 Oct;52(7):1174-1184. doi: 10.1111/apt.16039. Epub 2020 Aug 14. Aliment Pharmacol Ther. 2020. PMID: 32794599

1. Vasudevan A, Parthasarathy N, Con D, et al. Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52:1174-1184.
1. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50:485-489.
1. Hanauer SB, Sandborn WJ, Lichtenstein GR. Evolving considerations for thiopurine therapy for inflammatory bowel diseases - a clinical practice update: commentary. Gastroenterology. 2019;156:36-42.
1. Gisbert JP, Gomollón F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol. 2008;103:1783-1800.
1. Lees CW, Maan AK, Hansoti B, Satsangi J, Arnott ID. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:220-227.